Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Avidity Biosciences, maintaining a price target of $96.
September 16, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Avidity Biosciences, maintaining a price target of $96, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests positive sentiment and potential upside for Avidity Biosciences' stock. This could lead to increased investor interest and buying pressure in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100